Monthly Archives: December 2019

Capstone’s Single Largest Combined Heat and Power Installation of Microturbine Technology Enters into a 9-Year Comprehensive Long-Term Service Contract

VAN NUYS, CA / ACCESSWIRE / December 11, 2019 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that E-Finity Distributed Generation, Capstone's exclusive distributor for the Mid-Atlantic, Southeastern United States and the Caribbean, signed a long-term Factory Protection Plan (FPP) service contract covering Capstone's single largest combined heat and power (CHP) installation with 5 megawatts (MW) of Capstone Microturbines.

"I am extremely pleased with our Capstone aftermarket business, including long-term FPP service contracts, Distributor Support Systems (DSS) program, as well as our new long-term microturbine rental fleet as all three of these initiatives continue to deliver steady revenue growth and solid contribution margins," stated Darren Jamison, Capstone's President and Chief Executive Officer.

"While all of the offerings from our aftermarket business are important to Capstone, it is the FPP with its stable, predictable, long-term revenue and positive cash flow that really underpins both our near-term positive Adjusted EBITDA plans and our long-term sustainability and profitability outlook. The 5 MW CHP installation, now with its new 9-year FPP, is expected to benefit both Capstone and the end-use customer jointly over the life of the project, making it truly a long-term win-win energy partnership," concluded Mr. Jamison.

Capstone Turbine's 9-year 5 MW Comprehensive Service Program

The five new Signature Series C1000's are commonly ducted together to inject the turbines' exhaust thermal energy directly into a drying process for a large ceramic tile manufacturer in the United States. This 9-year FPP will provide comprehensive service coverage, including engine overhauls, as well as all scheduled and unscheduled maintenance at a fixed cost for the entire 9-year term. The Capstone microturbines, commissioned in late October 2019, are used for 24×7 electrical and thermal generation and are configured with Capstone Dual-Mode technology that will "island" the power plant and provide back-up electrical and thermal power to plant operations in the event of a local grid power outage.

"E-Finity sets the standard for aftermarket support for their large fleet of Capstone Microturbines, and with this win, they now have 54 MW under the Capstone innovative FPP program," said Jeff Foster, Capstone's Senior Vice President of Customer Service and Product Development. "With this latest Energy Efficiency FPP contract coming on the heels of a number of large Oil & Gas FPP contracts, our flexible FPP offering has become the backbone for continuing the top-line growth of our high margin aftermarket business," added Mr. Foster.

"The continued high adoption rate of our FPP, now with 54% of eligible customers covered, is driving our profitable aftermarket business to new highs," stated Jen Derstine, Capstone's Vice President of Marketing and Distribution. "By securing this newest contract, we have set another record of having 263 MWs covered under long-term service contracts, which provides the backbone for recurring, predictable, profitable revenue streams for many years and is a great asset to all our stakeholders including our distribution partners who perform the work under the FPP contract on behalf of Capstone," concluded Mrs. Derstine.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq: CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, providing scalable systems focusing on 30 kWs to 10 MWs that operate on a variety of gaseous or liquid fuels and are the ideal solution for today's distributed power generation needs. To date, Capstone has shipped over 9,000 units to 73 countries and have saved customers an estimated $253 million in annual energy costs and 350,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 569825

Gemini Group Global Corp. Enters into Agreement for Drilling Program

DALLAS, TX / ACCESSWIRE / December 11, 2019 / Gemini Group Global Corp. (OTC PINK:GMNI) today announced they have entered into a letter of intent and master purchase agreement with Flintrock Resources Management Inc. The agreement pertains to the purchase of working interest (WI) in the exploration and production of minerals focusing specifically in oil and gas. Flintrock Resources Management Inc. will be the main operating company delivering Net Revenue Interest (NRI) to Gemini Group Global Corp. The companies collectively will be focused on offset drilling in proven properties that are located in the Midland and Permian Basin respectively.

Subject to the negotiation and execution of a definitive agreement, the initial project Gemini Group Global Corp. (OTC:GMNI) will focus on collectively is the Lohn Prospect. The Lohn Prospect is roughly 219 acres on the eastern shelf of the Midland Basin Located in McCulloch County, TX with proven reserves of 116 Million Barrels of Oil (MBO). The areais prolific with formations that include the Pennsylvania (Strawn), Morris, and Llano uplift. Gemini Group Global Corp. (OTC:GMNI) is expected to commence investing in drilling operations in the Lohn Prospect in the first quarter of 2020. The drilling program consists of up to Ten offset wells with an average depth of roughly 1300 feet.

"We are excited to be working with Flintrock Resources Management Inc. as the company moves forward with our focus on sustainable growth for our shareholders. Flintrock Resources has a proven track record of success in Texas and we feel confident that together we will create real value andrevenue for the shareholders of Gemini Group Global Corp".

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number ofassumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Contact:

888.543.5551
info@geminivapour.com

SOURCE: Gemini Group Global Corp.

ReleaseID: 569817

VSB Bancorp, Inc. Announces our Forty-Ninth Consecutive Cash Dividend and a 15% Increase in the Quarterly Cash Dividend

STATEN ISLAND, NY / ACCESSWIRE / December 11, 2019 / VSB Bancorp, Inc. (OTCQX:VSBN), the holding company for Victory State Bank, announced today that its Board of Directors has declared a quarterly cash dividend of $0.15 per share, payable on January 2, 2020, an increase of 15%, to stockholders of record on December 20, 2019. Joseph J. LiBassi, Chairman of the Board of Directors, stated, "We are pleased to announce our forty-ninth consecutive cash dividend. We increased the quarterly cash dividend by two cents per share based upon our continued strong earnings."

Raffaele M. Branca, President and Chief Executive Officer, reported, "Our dividend payout ratio is 23.7% on third quarter 2019 earnings. This is the second increase in our quarterly cash dividend rate this year."

VSB Bancorp, Inc. is the one-bank holding company for Victory State Bank. Victory State Bank, a Staten Island based commercial bank, commenced operations on November 17, 1997. The Bank's initial capitalization of $7.0 million was primarily raised in the Staten Island community. The Bancorp's total equity stood at $38.1 million by September 30, 2019. The Bank operates six full service locations in Staten Island, the main office at 4142 Hylan Boulevard in Great Kills and branches on Forest Avenue in West Brighton, Hyatt Street in St. George, Hylan Boulevard in Dongan Hills, Bay Street in Rosebank and Victory Boulevard in Meiers Corners.

The payment of dividends is at the discretion of the Board of Directors and nothing contained herein should be interpreted as a commitment to pay future dividends.

Statements contained in this press release, which are not historical facts, are forward -looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to materially differ from those currently anticipated. Those risks and uncertainties include, among other things, possible future changes in (i) the local, regional or national economy, (ii) market interest rates, (iii) customer preferences, (iv) competition or (v) federal or state laws.

Contact Name:

Ralph M. Branca
President & CEO
(718) 979-1100

SOURCE: VSB Bancorp

ReleaseID: 569794

CounterPath Reports Second Quarter Fiscal 2020 Financial Results

Year-over-Year Recurring Revenue Growth of 14%

VANCOUVER, BC / ACCESSWIRE / December 11, 2019 / CounterPath Corporation (NASDAQ:CPAH)(TSX:PATH) (the "Company" or "CounterPath"), a global provider of award-winning Unified Communications (UC) solutions for enterprises and service providers, today announced the financial and operating results for its quarter ended October 31, 2019, being the second quarter of fiscal year 2020.

Second Quarter Financial Highlights (unaudited)

Revenue increased by 11% to $2.7 million compared to revenue of $2.4 million for the second quarter of fiscal 2019.
Billings (revenue plus change in deferred revenue) increased by 19% to $3.0 million, compared to $2.5 million for the second quarter of fiscal 2019.
Growth in subscription, support and maintenance revenue (revenue of a recurring nature) of 14% for the quarter compared to the second quarter of fiscal 2019.
Non-GAAP loss from operations of $0.7 million compared to non-GAAP loss from operations of $2.0 million for the second quarter of fiscal 2019.
Net loss of $0.8 million, or $0.13 per share, compared to net loss of $2.1 million, or $0.35 per share, for the second quarter of fiscal 2019.
Non-GAAP net loss of $0.7 million, or $0.12 per share, compared to non-GAAP net income of $2.0 million, or $0.34 per share, for the second quarter of fiscal 2019.
Cash of $1.9 million as of October 31, 2019 compared to cash of $1.9 million as of April 30, 2019.

Management Commentary

"Several financial metrics were strong during the quarter," said David Karp, CEO. "While overall revenue grew, our recurring revenue reached a record level of $1.5 million during the quarter, or 56% of total revenue owing to our continuing effort to move our licensing model to recurring revenue. Our billings reached $3 million, which included the renewal of two significant annual contracts by longtime customers in the call center vertical. At the same time, we have been gradually reducing our costs over the last year, without significantly impacting our ability to maintain and grow revenue. As a result, our operating expenses declined by 25% from the same quarter in previous year. Next quarter we expect to see our cash operating costs to be at their lowest level in the last two fiscal years.

Our sales focus will continue to be on growing recurring revenue. In that regard, after the quarter, we introduced Bria Solo, a subscription offering to replace our Bria 5 softphone solution. Bria Solo is also available with fewer features as a free version that replaces our flagship X-Lite softphone. Bria Solo is intended for single softphone users and is a pathway to Bria Teams and Bria Enterprise. Unlike X-Lite, Bria Solo introduces a feature-rich Bria trial experience that is expected to enable CounterPath to improve conversions from free-to-paid, better monetizing our extensive X-Lite user base. Together, Bria Solo and Bria Teams offer compelling unified communication solutions to the underserved small and medium sized enterprise market."

Recent Business Highlights

Advanced the Contact Center Channel Partner business with Bria softphones and the Stretto Platform™ to enable a highly secure, subscription-based offering that overlays with channel partners' contact center deployments.
Expanded the Stretto Collaboration solution with the launch of a hosted services including virtual meeting room and video conferencing services for the rapidly expanding global network of CounterPath channel partners throughout North America, Europe and other key markets.
Announced that TMC, a global, integrated media company, has named Bria for Call Center as a 2019 Contact Center Technology Award winner, presented by CUSTOMER magazine.
Announced that three reseller partners have successfully developed Customer Relationship Management (CRM) integrations with Bria softphones.

Financial Overview

(All amounts in U.S. dollars and in accordance with accounting principles generally accepted in the United States ("GAAP") unless otherwise specified – unaudited).

Revenue was $2.7 million for the quarter ended October 31, 2019 compared to $2.4 million for the same quarter in the last fiscal year. Software revenue was $1.0 million compared to $0.9 million for the same quarter in the last fiscal year, subscription, support and maintenance revenue was $1.5 million compared to $1.3 million for the same quarter in the last fiscal year, and professional services and other revenue was $0.2 million compared to $0.2 million for the same quarter in the last fiscal year.

Operating expenses for the quarter ended October 31, 2019 were $3.4 million compared to $4.5 million for the same quarter in the last fiscal year. Operating expenses for the quarter ended October 31, 2019 included a non-cash stock-based compensation expense of $0.1 million (2018 – $0.1 million). Cost of sales was $0.6 million for the quarter ended October 31, 2019 compared to $0.6 million for the same quarter in the last fiscal year. Sales and marketing expenses were $1.0 million for the quarter ended October 31, 2019 compared to $1.0 million for the same quarter last fiscal year. For the quarter ended October 31, 2019, research and development expenses were $1.2 million and general and administrative expenses were $0.7 million compared to $1.4 million and $1.6 million, respectively, for the same quarter in the last fiscal year.

Interest and other (expense) income, net for the quarter ended October 31, 2019 was ($0.1) million compared to $0.03 million for the same quarter in the last fiscal year. Interest and other (expense) income, net was primarily comprised of interest expense of $0.08 million related to the loan payable and a foreign exchange loss of $0.01 million, compared to a foreign exchange gain of $0.04 million and a loss on fair value of derivative instruments of $0.01 million for the same quarter in the last fiscal year. The foreign exchange gain (loss) represents the gain (loss) on account of translation of the intercompany accounts of the Company's subsidiary which are maintained in Canadian dollars and transactional gains and losses resulting from transactions denominated in currencies other than U.S. dollars.

The net loss for the quarter ended October 31, 2019 was $0.8 million, or $0.13 per share, compared to a net loss of $2.1 million, or $0.35 per share, for the same quarter in the last fiscal year. As of October 31, 2019, the Company had $1.9 million in cash, compared to $1.9 million at April 30, 2019.

Forward-Looking Statements

This news release contains "forward-looking statements". Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future, including the statements (1) at the same time, we have been gradually reducing our costs over the last year, without significantly impacting our ability to maintain and grow revenue; (2) next quarter the Company expects to see its cash operating costs to be at their lowest level in the last two fiscal years; and (3) unlike X-Lite, Bria Solo introduces a feature-rich Bria trial experience that is expected to enable CounterPath to improve conversions from free-to-paid, better monetizing our extensive X-Lite user base. It is important to note that actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (1) the lack of cash flow which may affect the Company's ability to continue as a going concern; (2) the variability in the Company's sales from reporting period to reporting period due to extended sales cycles as a result of selling the Company's products through channel partners or the length of time of deployment of the Company's products by its customers; (3) the Company's ability to manage its operating expenses, which may adversely affect its financial condition and ability to continue to operate as a going concern; (4) the Company's ability to remain competitive as other better financed competitors develop and release competitive products; (5) a decline in the Company's stock price or insufficient investor interest in the Company's securities which may impact the Company's ability to raise additional financing as required or may cause the Company to be delisted from a stock exchange on which its common stock trades; (6) the impact of intellectual property litigation that could materially and adversely affect the Company's business; (7) the success by the Company of the sales of its current and new products; (8) the impact of technology changes on the Company's products and industry; (9) the failure to develop new and innovative products using the Company's technologies including the refresh of our Software-as-a Service (SaaS) solution; and (10) the potential dilution to shareholders or overhang on the Company's share price of its outstanding stock options. Readers should also refer to the risk disclosures outlined in the Company's quarterly reports on Form 10-Q, the Company's annual reports on Form 10-K, and the Company's other disclosure documents filed from time-to-time with the Securities and Exchange Commission at www.sec.gov and the Company's interim and annual filings and other disclosure documents filed from time-to-time on SEDAR at www.sedar.com.

About CounterPath

CounterPath Corporation (NASDAQ: CPAH) is revolutionizing how people communicate in today's modern mobile workforce. Its award-winning Bria solutions for desktop and mobile devices enable organizations to leverage their existing PBX or hosted VoIP service to extend seamless and secure unified communications and collaboration to users regardless of their location and network. CounterPath technology meets the unique requirements of several industries, including contact center, retail, warehouse, hospitality, and healthcare verticals. Its solutions are deployed world-wide by 8×8, Airbnb, AmeriSave, BT, Citibank, Comcast, Fusion, Fuze, Liberty Global, Uber, Windstream and others. Learn more at counterpath.com and follow on Twitter @counterpath.

Contacts:

David Karp
Chief Executive Officer
dkarp@counterpath.com

(TABLES TO FOLLOW)
COUNTERPATH CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Stated in U.S. Dollars)

 

 
October 31,
 
 
April 30,
 

 

 
2019
 
 
2019
 

 

 
 
 
 
 
 

Assets

 
 
 
 
 
 

Current assets:

 
 
 
 
 
 

Cash

 
$
1,853,216
 
 
$
1,862,458
 

Accounts receivable (net of allowance for doubtful accounts of $447,118 (2019 – $619,514))

 
 
1,475,240
 
 
 
1,876,896
 

Deferred sales commission costs – current

 
 
141,981
 
 
 
122,777
 

Derivative assets

 
 
6,255
 
 
 
1,178
 

Prepaid expenses and other current assets

 
 
174,981
 
 
 
263,078
 

Total current assets

 
 
3,651,673
 
 
 
4,126,387
 

 

 
 
 
 
 
 
 
 

Deposits

 
 
96,541
 
 
 
94,829
 

Deferred sales commission costs – non-current

 
 
80,777
 
 
 
77,571
 

Equipment

 
 
65,565
 
 
 
59,914
 

Operating lease right-of-use assets

 
 
1,556,568
 
 
 

 

Goodwill

 
 
6,677,299
 
 
 
6,541,290
 

Intangibles and other assets

 
 
226,375
 
 
 
224,795
 

Total Assets

 
$
12,354,798
 
 
$
11,124,786
 

 

 
 
 
 
 
 
 
 

Liabilities and Stockholders' Equity

 
 
 
 
 
 
 
 

Current liabilities:

 
 
 
 
 
 
 
 

Accounts payable and accrued liabilities

 
$
1,988,620
 
 
$
2,233,875
 

Derivative liability

 
 
379
 
 
 
4,512
 

Unearned revenue

 
 
2,813,753
 
 
 
2,593,726
 

Other current liabilities

 
 

 
 
 
947
 

Accrued warranty

 
 
44,319
 
 
 
52,035
 

Operating lease liabilities – current

 
 
259,612
 
 
 

 

Total current liabilities

 
 
5,106,683
 
 
 
4,885,095
 

 

 
 
 
 
 
 
 
 

Deferred lease inducements

 
 

 
 
 
4,031
 

Loan payable

 
 
4,000,000
 
 
 
3,000,000
 

Operating lease liabilities – non-current

 
 
1,315,677
 
 
 

 

Unrecognized tax liability

 
 
9,763
 
 
 
9,763
 

Total liabilities

 
 
10,432,123
 
 
 
7,898,889
 

 

 
 
 
 
 
 
 
 

Stockholders' equity:

 
 
 
 
 
 
 
 

Preferred stock, $0.001 par value

 
 
 
 
 
 
 
 

Authorized: 100,000,000

 
 
 
 
 
 
 
 

Issued and outstanding: October 31, 2019 – nil; April 30, 2019 – nil

 
 

 
 
 

 

Common stock, $0.001 par value

 
 
 
 
 
 
 
 

Authorized: 100,000,000

 
 
 
 
 
 
 
 

Issued:

 
 
 
 
 
 
 
 

October 31, 2019 – 5,957,585; April 30, 2019 – 5,950,246

 
 
5,957
 
 
 
5,950
 

Additional paid-in capital

 
 
75,802,284
 
 
 
75,667,533
 

Accumulated deficit

 
 
(70,312,063
)
 
 
(68,581,091
)

Accumulated other comprehensive loss – currency translation adjustment

 
 
(3,573,503
)
 
 
(3,866,495
)

Total stockholders' equity

 
 
1,922,675
 
 
 
3,225,897
 

Liabilities and Stockholders' Equity

 
$
12,354,798
 
 
$
11,124,786
 

 

 
 
 
 
 
 
 
 

COUNTERPATH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Stated in U.S. Dollars)
(Unaudited)

 

 
Three Months Ended
 
 
Six Months Ended
 

 

 
October 31,
 
 
October 31,
 

 

 
2019
 
 
2018
 
 
2019
 
 
2018
 

Revenue:

 
 
 
 
 
 
 
 
 
 
 
 

Software

 
$
1,042,208
 
 
$
923,416
 
 
$
2,052,032
 
 
$
2,279,418
 

Subscription, support and maintenance

 
 
1,502,944
 
 
 
1,319,840
 
 
 
2,924,806
 
 
 
2,570,860
 

Professional services and other

 
 
155,770
 
 
 
198,005
 
 
 
297,752
 
 
 
478,813
 

Total revenue

 
 
2,700,922
 
 
 
2,441,261
 
 
 
5,274,590
 
 
 
5,329,091
 

Operating expenses:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Cost of sales

 
 
562,619
 
 
 
623,811
 
 
 
1,073,979
 
 
 
1,219,367
 

Sales and marketing

 
 
955,010
 
 
 
967,689
 
 
 
1,925,603
 
 
 
1,962,649
 

Research and development

 
 
1,233,994
 
 
 
1,391,737
 
 
 
2,365,842
 
 
 
2,794,693
 

General and administrative

 
 
655,273
 
 
 
1,550,101
 
 
 
1,299,986
 
 
 
2,541,739
 

Total operating expenses

 
 
3,406,896
 
 
 
4,533,338
 
 
 
6,665,410
 
 
 
8,518,448
 

Loss from operations

 
 
(705,974
)
 
 
(2,092,077
)
 
 
(1,390,820
)
 
 
(3,189,357
)

Interest and other (expense) income, net:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Interest expense

 
 
(82,217
)
 
 
(4,661
)
 
 
(152,790
)
 
 
(4,666
)

Foreign exchange (loss) gain

 
 
(14,620
)
 
 
43,535
 
 
 
(189,510
)
 
 
124,471
 

Change in fair value of derivative instruments

 
 
9,608
 
 
 
(10,554
)
 
 
10,194
 
 
 
(5,152
)

Loss on lease termination

 
 
(8,746
)
 
 

 
 
 
(8,746
)
 
 

 

Other income

 
 
700
 
 
 

 
 
 
700
 
 
 

 

Total interest and other (expense) income, net

 
 
(95,275
)
 
 
28,320
 
 
 
(340,152
)
 
 
114,653
 

Net loss for the period

 
$
(801,249
)
 
$
(2,063,757
)
 
$
(1,730,972
)
 
$
(3,074,704
)

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net loss per share:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic and diluted

 
$
(0.13
)
 
$
(0.35
)
 
$
(0.29
)
 
$
(0.52
)

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Weighted average common shares outstanding:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic and diluted

 
 
5,955,954
 
 
 
5,941,812
 
 
 
5,954,038
 
 
 
5,937,115
 

Non-GAAP Financial Measures

This news release contains "non-GAAP financial measures". The non-GAAP financial measures in this news release consist of non-GAAP loss from operations which excludes non-cash stock-based compensation relative to loss from operations calculated in accordance with GAAP and non-GAAP net loss which excludes non-cash stock-based compensation, foreign exchange gain (loss) and change in fair value of derivative instruments relative to net loss calculated in accordance with GAAP. The non-GAAP financial measures in this news release also include billings which is calculated as revenue recognized plus the change in deferred revenue from the beginning to the end of the applicable period. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. CounterPath utilizes both GAAP and non-GAAP financial measures to assess what it believes to be its core operating performance and to evaluate and manage its internal business and assist in making financial operating decisions. CounterPath believes that the inclusion of non-GAAP financial measures, together with GAAP measures, provides investors with an alternative presentation useful to investors' understanding of CounterPath's core operating results and trends.

Reconciliation to GAAP
(Unaudited)

 

 
Three Months Ended
 
 
Six Months Ended
 

 

 
October 31,
 
 
October 31,
 

 

 
2019
 
 
2018
 
 
2019
 
 
2018
 

Non-GAAP loss from operations:

 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 

GAAP loss from operations

 
$
(705,974
)
 
$
(2,092,077
)
 
$
(1,390,820
)
 
$
(3,189,357
)

Plus:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Stock-based compensation

 
 
55,763
 
 
 
72,185
 
 
 
124,103
 
 
 
339,597
 

Non-GAAP loss from operations

 
$
(650,211
)
 
$
(2,019,892
)
 
$
(1,266,717
)
 
$
(2,849,760
)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
Three Months Ended
 
 
Six Months Ended
 

 

 
October 31,
 
 
October 31,
 

 

 
2019
 
 
2018
 
 
2019
 
 
2018
 

Non-GAAP net loss:

 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 

GAAP net loss

 
$
(801,249
)
 
$
(2,063,757
)
 
$
(1,730,972
)
 
$
(3,074,704
)

Plus:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Stock-based compensation

 
 
55,763
 
 
 
72,185
 
 
 
124,103
 
 
 
339,597
 

Foreign exchange loss (gain)

 
 
14,620
 
 
 
(43,535
)
 
 
189,510
 
 
 
(124,471
)

Change in fair value of derivative instruments

 
 
(9,608
)
 
 
10,554
 
 
 
(10,194
)
 
 
5,152
 

Non-GAAP net loss

 
$
(740,474
)
 
$
(2,024,553
)
 
$
(1,427,553
)
 
$
(2,854,426
)

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

GAAP net loss per share:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic and diluted

 
$
(0.13
)
 
$
(0.35
)
 
$
(0.29
)
 
$
(0.52
)

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Non-GAAP net loss per share:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic and diluted

 
$
(0.12
)
 
$
(0.34
)
 
$
(0.24
)
 
$
(0.48
)

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
Three Months Ended
 
 
Six Months Ended
 

 

 
October 31,
 
 
October 31,
 

 

 
2019
 
 
2018
 
 
2019
 
 
2018
 

Billings:

 
 
 
 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 

Revenue

 

2,700,922
 
 

2,441,261
 
 

5,274,590
 
 

5,329,091
 

Add: Deferred revenue, end of period

 
 
2,813,753
 
 
 
2,597,465
 
 
 
2,813,753
 
 
 
2,597,465
 

Less: Deferred revenue, beginning of period

 
 
(2,553,510
)
 
 
(2,558,932
)
 
 
(2,593,726
)
 
 
(2,565,876
)

Non-GAAP Billings

 

2,961,165
 
 

2,479,794
 
 

5,494,617
 
 

5,360,680
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

SOURCE: CounterPath Corporation

ReleaseID: 569811

TechCrunch Selects Apostera As A Top Five AI Startup For Disrupt Berlin 2019 Event

MUNICH, GERMANY / ACCESSWIRE / December 11, 2019 / Apostera GmbH, an automotive technology company that delivers revolutionary info-ADAS mixed reality products to global OEMs, today announced that it was selected among top five companies within Artificial Intelligence and Machine Learning Category by TechCrunch for its Disrupt Berlin 2019.

Disrupt Berlin will take place on December 11-12, 2019. The program showcases outstanding early-stage enterprises across nine categories: AI/Machine Learning, Biotech/Healthtech, Blockchain, Fintech, Mobility, Privacy/Security, Retail/E-commerce, Robotics/IoT/Hardware, and CRM/Enterprise. This event brings together thousands of talented start-up companies representing more than 50 countries around the globe, numerous venture capital funds, technology gurus, and other thought leaders.

Apostera booth will be located in the StartUp Alley, space# I2. Startup Alley is the heart of Disrupt Berlin where hundreds of pre-series A startups and sponsors across all verticals will be showcasing their latest tech products, platforms and services.

Apostera will exhibit Mixed Reality Navigation Guidance solution that merges the virtual and real worlds that makes the driving experience more enjoyable, safe and carefree by providing transparency and predictability of oncoming terrain delivering optimal time for the driver to strategize and react.

Andrey Golubinsky, CEO and Managing Director of Apostera commented: "We are honored to be named among the top five companies in our area by TechCrunch and excited that our solutions and expertise will harness so much attention from such a diverse talented and creative audience at Disrupt Berlin…. "

About Apostera

Apostera is a next generation augmented reality, R&D, and software engineering company, providing proprietary product and expert integration services for automotive sector worldwide. The Company offers turnkey product and design services across key aspects of Advance Driver Assist Systems (ADAS), creating mixed reality software ready for end-to-end vehicle integration. Apostera's AR Platform combines most sophisticated modern techniques to host advanced driver assistance applications: Augmented Reality, Smart Camera, Surround View Monitoring. The platform helps OEMs to seamlessly and efficiently resolve multiple complexities inherently present in building reliable, safe navigation and other vehicle positioning-related solutions expected by consumers in all vehicles of today. Apostera's solutions aid proper data rendering and effective visualization at vehicle speeds of up to 300 km/h, which allow the driver and the vehicle safely adjust to sudden topography, slope and trajectory changes, all-directional collision warnings, etc. Apostera is based in Munich, Germany delivering its services and solutions to global OEMs through the power and knowledge of over 90 advanced software engineers and data scientists. More information can be found at www.apostera.com

Press inquiries:

Email: pr@apostera.com
Phone: +49 89 9017072-0

SOURCE: Apostera GmbH

ReleaseID: 569840

Humanigen’s GM-CSF Knockout Data Presented at the 2019 Annual Meeting of American Society of Hematology Receives Award

Improved survival demonstrated with GM-CSF knockout CAR-T
GM-CSF knockout CAR-T results in altered gene transcriptome with decreased death receptors including Fas
Presentation received an ASH Abstract Achievement Award

BURLINGAME, CA / ACCESSWIRE / December 11, 2019 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on the development of next generation chimeric antigen receptor T cell (CAR-T) and other cell therapies, presented results from the study of granulocyte-macrophage colony-stimulating factor (GM-CSF) gene knockout (k/o) CAR-T cells and GM-CSF neutralization with lenzilumab, the company's proprietary Humaneered® anti-human-GM-CSF monoclonal antibody, at the 2019 annual meeting of the American Society of Hematology (ASH).

The presentation, entitled "Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated CARTs" by Michelle Cox and colleagues was delivered on Monday, December 9, 2019.

Using a xenograft model for relapsed acute lymphoblastic leukemia (ALL), treatment with GM-CSF k/o CART19 resulted in improved overall survival compared to wildtype CART19. The lack of myeloid cells in this model pointed to an intrinsic effect of GM-CSF on CAR-T cells.

While resting CAR-T cells do not express GM-CSF receptors, the data demonstrate that activated CAR-T cells significantly upregulate GM-CSF receptors and signal through these receptors. GM-CSF k/o CAR-T cells show a distinct transcriptome signature that more closely resembles untransduced T cells than wildtype CAR-T cells based on principle component analysis. There also appeared to be significant inhibition of death receptor expression including the Fas death pathway receptor, a known critical pathway in inducing CAR-T cell death, with GM-CSF knockout CAR-T. This may also mean that CAR-T cells with GM-CSF k/o could be viewed as fitter T cells, which have been associated with improved durable efficacy. Collectively, these results illuminate a novel mechanism for a direct modulatory effect of GM-CSF on activated CAR-T cells that helps to explain the improved survival with GM-CSF neutralization or knockout.

The presentation received a 2019 ASH Abstract Achievement Award.

The abstract, entitled "Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated CARTs" can be accessed at: https://ash.confex.com/ash/2019/webprogram/Paper129349.html

"It is gratifying to receive recognition for the second year in succession that we have presented GM-CSF -related data for the pioneering work that we are conducting to make CAR-T therapy potentially more efficacious and safer through GM-CSF neutralization" stated Dr. Cameron Durrant, CEO of Humanigen. "We are looking forward to bringing lenzilumab into the clinic as we begin dosing patients in ZUMA-19 in 2020 with our partner, Kite Pharma".

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company's immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company's proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline. For more information, visit www.humanigen.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for future development of lenzilumab to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Black Horse Capital and its affiliates owning more than 50% of our outstanding common stock, including their ability to control the company; our lack of profitability and need for additional capital to operate our business as a going concern; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:
Media:
Chris Bowe – 646-662-7628
cbowe@humanigen.com

SOURCE: Humanigen, Inc.

ReleaseID: 569839

Leafbuyer Technologies, Inc. Launches Comprehensive Cannabis Mobile Application

Leafbuyer Technologies, Inc. Combines Multiple Platforms, Loyalty, Delivery, Order Ahead, and More, in One Mobile Application

DENVER, CO / ACCESSWIRE / December 11, 2019 / Leafbuyer Technologies, Inc. ("Leafbuyer" or "the Company")(OTCQB:LBUY) announced today the launch of its eagerly anticipated, all-encompassing mobile application.

"This is the biggest launch of the year. We are very proud of this application and believe it to be the most comprehensive tool in the cannabis industry," said Kurt Rossner, CEO of Leafbuyer.

The new application merges the functionality of Leafbuyer's current deals and mapping technology with order ahead and delivery functionality. Advanced filters within the app allow consumers to filter merchandise by location, THC and CBD content, flavor, effects, and more.

"Leafbuyer's free mobile application will increase communication, thus making Leafbuyer a more valuable marketing channel for dispensaries and product companies across the country," said Rossner. "The platform provides an effective channel for customers to order ahead or get products delivered from participating shops in legal markets."

Until now, Leafbuyer's product offerings were hosted on multiple platforms: on the former Leafbuyer app, the Greenlight app, and within tablets at participating dispensaries. The new application centralizes the consumer experience allowing single sign on access. It was developed for distribution on Google Play Store, iOS App Store, and through a PWA.

Consumers are now able to search for deals and businesses, order their favorite products for in-store pickup, get items delivered, and track loyalty points and transactions within one application. Visit Leafbuyer.com/app to download and learn more.

About Leafbuyer Technologies, Inc.

Leafbuyer.com is one of the most comprehensive online sources for cannabis deals and information. Leafbuyer works alongside businesses to showcase their unique products and build a network of loyal patrons. Leafbuyer's national network of cannabis deals and information reaches millions of consumers every month. Leafbuyer is the official cannabis deals platform of Dope Media, Sensi Magazine, and Voice Media Group.

Learn more at Leafbuyer.com.

Contacts

Leafbuyer Technologies, Inc.
Andre Leonard, +720-432-5593
aleonard@leafbuyer.com

Cautionary Statement Regarding Forward-Looking Information

Safe Harbor Statement

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in the forward-looking statements due to several factors detailed from time to time in our filings with the Securities and Exchange Commission. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings.

SOURCE: Leafbuyer Technologies, Inc. 

ReleaseID: 569823

KushCo Holdings Names HeavenlyRx, B GREAT, Maye, and Level Select as Next Four CBD Brand Partners Under its Retail Services Partnership with C.A. Fortune

CYPRESS, CA / ACCESSWIRE / December 11, 2019 / KushCo Holdings, Inc. (OTCQX:KSHB) ("KushCo" or the "Company"), the premier producer of ancillary products and services to the legal cannabis and CBD industries, today announced the addition of four new compliant, hemp-derived CBD brands under its Retail Services partnership with C.A. Fortune, a leading full-service national consumer products sales and marketing agency focused on lifestyle brand partnerships.

The four new hemp-derived CBD brands include:

HeavenlyRx: A global hemp and CBD company that holds controlling ownership interests in various industry-leading assets in the hemp/CBD and THC-free cannabinoid wellness space, with a focus on hemp cultivation, processing and the manufacturing of a diverse range of traditional CBD products including oils, tinctures, balms, and vape-ready products. HeavenlyRx recently signed a letter of intent to acquire a top-ranked national CBD brand, PureKana.

B GREAT: An emerging CBD brand that produces superior quality and full-spectrum hemp-based products, including topicals, tinctures, capsules, and hemp shots. All products use natural ingredients grown in the U.S., are produced in FDA-registered and GMP-compliant facilities, and are third-party lab tested.

Maye: An upcoming line of CBD products by Grassroots, the largest private vertically-integrated multi-state operator with a vast presence in legal cannabis and CBD markets, particularly across the Midwest and Northeast. With roots in medical cannabis, Maye's team of professionals have helped thousands of people across the country safely introduce the wellness benefits of cannabis and CBD into their daily lives.

Level Select: A breakthrough line of sports creams and sports roll-ons with a proprietary blend of broad spectrum and nano CBD for quick absorption. Level Select's operations span multiple geographies and farms throughout the U.S. and adhere to disciplined farming processes to guarantee high levels of quality CBD with no THC from farm to final product.

Along with the Company's first CBD brand partner, Sentia Wellness, a new hemp-derived CBD company with manufacturing and distribution capabilities, these brands will leverage KushCo's enhanced distribution capabilities through C.A. Fortune to expand their distribution into grocery and other conventional stores nationwide.

"For the past several months, we have been hard at work helping our CBD brands capture significant share in the rapidly growing, multi-billion-dollar CBD industry by onboarding them onto some of the largest national conventional retail chains," said Jason Vegotsky, KushCo's Chief Revenue Officer and President. "Currently, with the FDA still yet to deliver comprehensive guidance regarding the authorized use of CBD in food and beverage products, our market is to a large extent limited to tinctures and topicals. However, even at this early juncture, we have been able to successfully gain retailer authorizations and activate some of our brands across a variety of retail channels. We also have been building a portfolio of food and beverage-oriented CBD brand partners so that when the FDA does give guidance for these brands to include CBD in their products, we can quickly and successfully launch them into the major retailers. Regardless of the specific retail channel, brands trust and rely on us because of our deep understanding of the federal and state regulatory and compliance framework, as well as our robust distribution network to help them scale across the nation. Ultimately, this process will take time, just like any other consumer packaged goods industry, but we're encouraged to see this division gaining traction and continuing to drive higher value for our customers."

KushCo's Retail Services division is the first large scale go-to-market operation focused on helping compliant, hemp-derived CBD brands achieve mass distribution across legal markets throughout the U.S. By providing comprehensive retail solutions, insight, and strategic direction to its CBD brand partners, KushCo solves one of the biggest challenges for building a national CBD brand. In addition to enabling distribution into the national grocery chains through its partnership with C.A. Fortune, the Company is focused on helping its CBD brand partners expand into other retail channels, including pet care, convenience, and beauty categories.

Vegotsky continued: "Beyond driving significant value for our customers and helping us nurture deeper and stickier relationships with them, our Retail Services division generates 100% gross margins and is EBITDA accretive given its capital light business model. Yet perhaps the biggest value-add of this business is that it greatly enhances our competitive moat by complementing our other products and services in the CBD seed-to-sale supply chain, including our newly launched hemp trading business. In fact, we are already experiencing meaningful synergies between these two businesses, as brand owners and operators who want access to our retail distribution network are also seeking a reliable, consistent, and independently tested supply of hemp biomass and post-processed oil to develop their CBD products. This dynamic creates a virtuous cycle, whereby the more retail stores we can get our brands into, the more hemp inputs, packaging, and energy and natural products they will need from us. This demand is only expected to grow as the industry continues to expand. Overall, leveraging our ecosystem and cross-selling into our deep customer base have been the staples to our success over the past decade and will help define our future as we continue to solidify our presence in the rapidly growing and massive CBD industry."

About KushCo Holdings, Inc.

KushCo Holdings, Inc. (OTCQX:KSHB) (www.kushco.com) is the premier producer of ancillary products and services to the legal cannabis and CBD industries. KushCo Holdings' subsidiaries and brands provide product quality, exceptional customer service, compliance knowledge and a local presence in serving its diverse customer base.

Founded in 2010, KushCo Holdings has now sold more than 1 billion units to growers, processors and producers across North America, South America, and Europe.

The Company has been featured in media nationwide, including CNBC, Fox News, Yahoo Finance, Cheddar, Los Angeles Times, TheStreet.com, and Entrepreneur, Inc Magazine. While KushCo Holdings provides products and solutions to customers in the cannabis and CBD industries, it has no direct involvement with the cannabis plant or any products that contain THC.

For more information, visit www.kushco.com or call (888)-920-5874.

Forward-Looking Statements

This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent the Company's current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Company's management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: "potential," "look forward," "expect," "project," "believe," "dedicated," "building," or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward- looking statements made by the Company herein are often discussed in the Company's filings with the United States Securities and Exchange Commission (SEC), which are available at: www.sec.gov, and on the Company's website, at: www.kushco.com.

KushCo Holdings Contact

Investor Contact:
Najim Mostamand, CFA
Director of Investor Relations
714-539-7653
ir@kushco.com

SOURCE: KushCo Holdings, Inc.

ReleaseID: 569810

Milestone Scientific Partners with RedOne Medical to Distribute the CompuFlo Epidural System to VA and DoD Medical Facilities Worldwide

LIVINGSTON, NJ / ACCESSWIRE / December 11, 2019 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced that it has partnered with RedOne Medical, a leading medical device distributor and wholesaler serving the Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals, to distribute the CompuFlo™ Epidural System.

Charles Pollak, Founder and CEO of RedOne Medical, stated, "We are excited to partner with Milestone Scientific to improve healthcare outcomes for America's warfighter and veteran patients. This clinically proven technology is 99% effective in identifying the epidural space on the first attempt, 14% more successful in patients with high body mass index, and reduces procedure time by one minute. We are honored to support VA and DoD hospitals with this innovative healthcare solution."

Brent Johnston, President of Milestone Scientific, commented, "Partnering with RedOne will provide us access to all federal medical facilities worldwide and is just one of many strategic initiatives we will be implementing at Milestone Scientific in order to support the global rollout strategy of the CompuFlo Epidural System. We look forward to our future relationship with RedOne."

About RedOne Medical

RedOne Medical is a CVE-certified Service-Disabled Veteran-Owned Small Business (SDVOSB) located in Savannah, GA. Wholly owned and operated by a combat veteran, RedOne Medical is a leading medical device distributor and wholesaler serving the Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. RedOne Medical donates a portion of profits to leading charities as part of its mission to support veterans, military families and their communities.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

SOURCE: Milestone Scientific Inc.

ReleaseID: 569795

Ceres Holographics Awarded Horizon 2020 Funding to Accelerate Commercialization of Holographic Technology for Next-Generation Displays

€1.4 Million Euro Grant Enables Ceres to Drive Development of Replication and Production Technology to meet Automotive OEM Demand for Advanced Holographic AR-HUD and Transparent Display Systems

ST ANDREWS, SCOTLAND and LONDON, UK / ACCESSWIRE / December 11, 2019 / Ceres Holographics, an innovative developer of thin-film Holographic Optical Elements (HOEs) for next-generation transparent display (TD) and augmented reality heads-up-display (AR-HUD) solutions today announced reaching a key funding milestone to accelerate the commercialization of its unique HOE digital mastering and replication technology. To date, Ceres has secured €6.1M million euro in funding through both private investors and the European Commission Horizon 2020: Research & Innovation Program.

To view the full release with downloadable visuals and more, click here.

Key Takeaways

Funding will accelerate commercialization of Ceres holographic digital mastering and replication technology.
Ceres Holographic Optical Elements (HOEs) for windscreens enable the next-generation of automobile head-up displays.
Horizon 2020 is one of the world's most prestigious and competitive grant programs making nearly 80 billion euros of funding available.

About Ceres

Founded in 2009, in St. Andrews, Scotland, Ceres Holographics uses its proprietary technology to design, digitally master, and replicate next-generation Holographic Optical Elements (HOEs) for new transparent display (TD) and augmented reality heads up display (HUD) systems. With extensive knowledge of holographic photopolymer films and in-house expertise in photonics and light-guiding, Ceres works with partners and customers to deliver optical systems with precision-engineered, thin-film HOEs enabling mass-market applications in automotive, transportation, aerospace and wearable technology.

Contact:

Toni Sottak
toni@wiredislandpr.com
4088764418
media contact

SOURCE: Ceres Holographics

ReleaseID: 569761